Nesfatin-1 and caspase-cleaved cytokeratin-18: Promising biomarkers for Alzheimer's disease?

Basit Öğe Kaydı
dc.contributor.authorAlpua, M.
dc.contributor.authorKisa, U.
dc.date.accessioned2020-06-25T18:34:34Z
dc.date.available2020-06-25T18:34:34Z
dc.date.issued2019
dc.departmentKırıkkale Üniversitesi
dc.descriptionKISA, Ucler/0000-0002-8131-6810
dc.description.abstractOBJECTIVES: To investigate the use of nesfatin-1 and caspase-cleaved cytokeratin-18 serum levels as biomarkers in Alzheimer's disease. METHODS: The study group consisted of 39 patients with Alzheimer's disease (AD) and 39 controls. Demographic characteristics including gender, age, body mass index, mini-mental status examination (MMSE) and duration of disease were recorded. The ELISA method was used to measure serum nesfatin-1 and CCCK-18 levels in serum samples. RESULTS: Serum nesfatin-1 levels were statistically significantly higher in the AD patient group than in controls. There was no significant difference between the groups with regards to serum CCCK-18 levels. Pearson analysis showed no significant correlation between serum nesfatin-1, serum CCCK-18 levels, mini-mental status examination and disease duration. CONCLUSION: This study proved that serum nesfatin-1 levels can be used as a biomarker in Alzheimer's disease by showing a statistically significant high level of serum nesfatin-1 in patients with Alzheimer's disease. This is the first study to suggest that nesfatin-1 can be used as a biomarker in Alzheimer's disease. In addition, our study showed that CCCK-18 can be used as a prognostic biomarker for Alzheimer's disease. Further comprehensive studies should be done to clarify the use of serum nesfatin-1 and CCCK-18 levels as biomarkers for Alzheimer disease (Tab. 3, Fig. 2, Ref. 25).en_US
dc.description.sponsorshipKirikkale UniversityKirikkale Universityen_US
dc.description.sponsorshipThis study was funded by Kirikkale University with this title Financial support and sponsorship.en_US
dc.identifier.citationAlpua M, Kisa U. Nesfatin-1 and caspase-cleaved cytokeratin-18: Promising biomarkers for Alzheimer's disease? Bratisl Lek Listy. 2019;120(4):295-298.en_US
dc.identifier.doi10.4149/BLL_2019_046
dc.identifier.endpage298en_US
dc.identifier.issn0006-9248
dc.identifier.issn1336-0345
dc.identifier.issue4en_US
dc.identifier.pmid31023053
dc.identifier.scopus2-s2.0-85065396905
dc.identifier.scopusqualityQ2
dc.identifier.startpage295en_US
dc.identifier.urihttps://doi.org/10.4149/BLL_2019_046
dc.identifier.urihttps://hdl.handle.net/20.500.12587/7960
dc.identifier.volume120en_US
dc.identifier.wosWOS:000466105100009
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherComenius Univen_US
dc.relation.ispartofBratislava Medical Journal-Bratislavske Lekarske Listy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectnesfatin-1en_US
dc.subjectCCCK-18en_US
dc.subjectAlzheimer's diseaseen_US
dc.subjectmini-mental status examinationen_US
dc.titleNesfatin-1 and caspase-cleaved cytokeratin-18: Promising biomarkers for Alzheimer's disease?en_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Nesfatin-1 and caspase-cleaved cytokeratin-18.pdf
Boyut:
121.19 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu